Head-To-Head Survey: Urogen Pharma (URGN) and The Competition

Urogen Pharma (NASDAQ:URGN – Get Free Report) is one of 894 public companies in the “Pharmaceuticals” industry, but how does it contrast to its rivals? We will compare Urogen Pharma to related companies based on the strength of its earnings, institutional ownership, risk, profitability, analyst recommendations, dividends and valuation.

Risk and Volatility

Urogen Pharma has a beta of 1.68, suggesting that its stock price is 68% more volatile than the S&P 500. Comparatively, Urogen Pharma’s rivals have a beta of -0.05, suggesting that their average stock price is 105% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and price targets for Urogen Pharma and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Urogen Pharma 1 1 8 0 2.70
Urogen Pharma Competitors 7850 13806 25845 1039 2.41

Urogen Pharma currently has a consensus price target of $53.38, indicating a potential upside of 79.17%. As a group, “Pharmaceuticals” companies have a potential upside of 27.58%. Given Urogen Pharma’s stronger consensus rating and higher probable upside, research analysts plainly believe Urogen Pharma is more favorable than its rivals.

Insider and Institutional Ownership

91.3% of Urogen Pharma shares are owned by institutional investors. Comparatively, 32.6% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 4.8% of Urogen Pharma shares are owned by company insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Urogen Pharma and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Urogen Pharma -26.27% N/A -26.88%
Urogen Pharma Competitors -2,391.70% -206.08% -14.88%

Valuation & Earnings

This table compares Urogen Pharma and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Urogen Pharma $109.79 million -$153.49 million -22.57
Urogen Pharma Competitors $3.56 billion $3.19 billion 555.16

Urogen Pharma’s rivals have higher revenue and earnings than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Summary

Urogen Pharma beats its rivals on 7 of the 13 factors compared.

Urogen Pharma Company Profile

(Get Free Report)

UroGen Pharma Ltd. is a biopharmaceutical company focused on developing and commercializing treatments for cancers of the urinary tract. Its work centers on therapies delivered directly to the urinary system, including treatments for certain forms of urothelial cancer. The company’s products include Jelmyto, a mitomycin-based treatment delivered to the upper urinary tract for adults with low-grade upper tract urothelial cancer, and Zusduri, a mitomycin-based treatment for adults with recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer.

Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.